Natus Sensory today announced the acquisition of TheraB Medical, a medical technology company focused on advancing the treatment of neonatal jaundice through wearable phototherapy solutions.
TheraB Medical’s flagship product, SnugLit, which received FDA 510(k) clearance in January 2026, is a wearable phototherapy swaddle-style device designed to treat neonatal jaundice while allowing infants to remain close to caregivers, supporting bonding and family-integrated care models increasingly adopted by hospitals worldwide. The addition of wearable phototherapy complements Natus Sensory’s existing newborn care solutions, providing clinicians with greater flexibility to tailor treatment to individual patient needs.
“TheraB was founded to advance effective jaundice treatment, and SnugLit was developed to preserve the critical bond between mother and baby. Joining Natus Sensory accelerates our path forward, expanding future access for clinicians, hospitals, and families who need it most," said Alexa Jones, founder of TheraB Medical and inventor of SnugLit.
The acquisition reflects Natus Sensory’s continued investment in innovation within newborn care, strengthening its ability to support clinicians with reliable, clinically proven technologies while responding to evolving care models and expectations.
